Radionuclide therapy in oncology: Repeated administrations of high dose rate radiopharmaceuticals

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 11, 2004, Pages 1556-

  Palmedo, H ^a   Bucerius, J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETIDRONIC ACID RE 188; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; INJECTION; LETTER; ONCOLOGY; PROSTATE CANCER; RADIOISOTOPE THERAPY;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; NEOPLASMS; RADIATION ONCOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 9944240379     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1665-z     Document Type: Letter

References (4)

1. Valdés Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004;31:929-31.
2. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging 2002;29(10):1271-5.
3. Turner JH, Claringhold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991:27(9):1084-6.
4. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21(15):2869-75.